BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras
554 results:

  • 1. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.
    Bellone S; Jeong K; Halle MK; Krakstad C; McNamara B; Greenman M; Mutlu L; Demirkiran C; Hartwich TMP; Yang-Hartwich Y; Zipponi M; Buza N; Hui P; Raspagliesi F; Lopez S; Paolini B; Milione M; Perrone E; Scambia G; Altwerger G; Ravaggi A; Bignotti E; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Quick CM; Angioli R; Terranova C; Zaidi S; Nandi S; Alexandrov LB; Siegel ER; Choi J; Schlessinger J; Santin AD
    Proc Natl Acad Sci U S A; 2024 Apr; 121(17):e2321898121. PubMed ID: 38625939
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. BRAF Mutated and Morphologically Spitzoid tumors, a Subgroup of Melanocytic Neoplasms Difficult to Distinguish From True Spitz Neoplasms.
    Gerami P; Chen A; Sharma N; Patel P; Hagstrom M; Kancherla P; Geraminejad T; Olivares S; Biswas A; Bosenberg M; Busam KJ; de La Fouchardière A; Duncan LM; Elder DE; Ko J; Landman G; Lazar AJ; Lowe L; Massi D; Mihic-Probst D; Parker DC; Scolyer RA; Shea CR; Zembowicz A; Yun SJ; Blokx WAM; Barnhill RL
    Am J Surg Pathol; 2024 May; 48(5):538-545. PubMed ID: 38525831
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Identification of germline
    Pires C; Saramago A; Moura MM; Li J; Donato S; Marques IJ; Belo H; Machado AC; Cabrera R; Grünewald TGP; Leite V; Cavaco BM
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396644
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Regulation of epinephrine biosynthesis in hras-mutant paragangliomas.
    Li M; Richter S; Mohr H; Drukewitz S; Poser I; Stanke D; Calsina B; Martinez-Montes AM; Quinkler M; Timmers HJLM; Nölting S; Beuschlein F; Remde H; Opocher G; Rapizzi E; Pacak K; Pamporaki C; Robledo M; Liu L; Jiang J; Bornstein SR; Eisenhofer G; Fliedner SMJ; Bechmann N
    Endocr Relat Cancer; 2023 Dec; 30(12):. PubMed ID: 37902037
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Network pharmacology-based strategy to investigate the effect and mechanism of α-solanine against glioma.
    Wang C; Liu X; Guo S
    BMC Complement Med Ther; 2023 Oct; 23(1):371. PubMed ID: 37865727
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Spitz tumor with RAF1 fusion: A report of 3 cases.
    Donati M; Nosek D; Olivares S; Lemahieu J; Loontiens S; Mansour B; Gerami P; Kazakov DV
    Ann Diagn Pathol; 2023 Dec; 67():152215. PubMed ID: 37856952
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Clinical, Morphologic, and Molecular Features of Benign and Intermediate-grade Melanocytic tumors With Activating Mutations in MAP2K1.
    Fumero-Velázquez M; Hagstrom M; Dhillon S; Geraminejad T; Olivares S; Donati M; Nosek D; Waldenbäck P; Kazakov D; Sheffield BS; Tron VA; Gerami P
    Am J Surg Pathol; 2023 Dec; 47(12):1438-1448. PubMed ID: 37773074
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Molecular mechanism of lycorine in the treatment of glioblastoma based on network pharmacology and molecular docking.
    Su J; Huo M; Xu F; Ding L
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Mar; 397(3):1551-1559. PubMed ID: 37668687
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Neuroblastoma RAS viral oncogene homolog (n-ras) deficiency aggravates liver injury and fibrosis.
    Zheng K; Hao F; Medrano-Garcia S; Chen C; Guo F; Morán-Blanco L; Rodríguez-Perales S; Torres-Ruiz R; Peligros MI; Vaquero J; Bañares R; Gómez Del Moral M; Regueiro JR; Martínez-Naves E; Mohamed MR; Gallego-Durán R; Maya D; Ampuero J; Romero-Gómez M; Gilbert-Ramos A; Guixé-Muntet S; Fernández-Iglesias A; Gracia-Sancho J; Coll M; Graupera I; Ginès P; Ciudin A; Rivera-Esteban J; Pericàs JM; Frutos MD; Ramos Molina B; Herranz JM; Ávila MA; Nevzorova YA; Fernández-Malavé E; Cubero FJ
    Cell Death Dis; 2023 Aug; 14(8):514. PubMed ID: 37563155
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Agminated presentation of fusion-driven melanocytic neoplasms.
    Fumero-Velázquez M; Hagstrom M; Dhillon S; Olivares S; Jennings LJ; Dittman D; Sukhanova M; Arva NC; Goldstein SD; Theos A; Pavlidakey P; Carr Z; Gerami P
    J Cutan Pathol; 2023 Oct; 50(10):913-921. PubMed ID: 37407520
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Branchioma with a nested/organoid morphology: molecular profiling of a distinctive potentially misleading variant and reappraisal of potential relationship to CD34-positive/Rb1-deficient tumors of the neck.
    Baněčková M; Michal M; Vaněček T; Grossman P; Nikolov DH; Včelák R; Žalud R; Michal M; Agaimy A
    Virchows Arch; 2023 Oct; 483(4):541-548. PubMed ID: 37401932
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms.
    Liu M; Li N; Tang H; Chen L; Liu X; Wang Y; Lin Y; Luo Y; Wei S; Wen W; Chen M; Wang J; Zhang N; Chen J
    Oncologist; 2023 Sep; 28(9):e723-e736. PubMed ID: 37086484
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Cancer in Costello syndrome: a systematic review and meta-analysis.
    Astiazaran-Symonds E; Ney GM; Higgs C; Oba L; Srivastava R; Livinski AA; Rosenberg PS; Stewart DR
    Br J Cancer; 2023 Jun; 128(11):2089-2096. PubMed ID: 36966234
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. hras overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors.
    Liverani C; Spadazzi C; Ibrahim T; Pieri F; Foca F; Calabrese C; De Vita A; Miserocchi G; Cocchi C; Vanni S; Ercolani G; Cavaliere D; Ranallo N; Chiadini E; Prisinzano G; Severi S; Sansovini M; Martinelli G; Bongiovanni A; Mercatali L
    Front Endocrinol (Lausanne); 2022; 13():1045038. PubMed ID: 36743926
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. An update on genomic aberrations in Spitz naevi and tumours.
    Hagstrom M; Fumero-Velázquez M; Dhillon S; Olivares S; Gerami P
    Pathology; 2023 Mar; 55(2):196-205. PubMed ID: 36631338
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Genomic Alterations and tumor Mutation Burden in Merkel cell Carcinoma.
    Brazel D; Kumar P; Doan H; Pan T; Shen W; Gao L; Moyers JT
    JAMA Netw Open; 2023 Jan; 6(1):e2249674. PubMed ID: 36602798
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Primary mucosal melanomas of the head and neck are characterised by overexpression of the DNA mutating enzyme APOBEC3B.
    Argyris PP; Naumann J; Jarvis MC; Wilkinson PE; Ho DP; Islam MN; Bhattacharyya I; Gopalakrishnan R; Li F; Koutlas IG; Giubellino A; Harris RS
    Histopathology; 2023 Mar; 82(4):608-621. PubMed ID: 36416305
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Paraganglioma with High Levels of Dopamine, Dopa Decarboxylase Suppression, Dopamine β-hydroxylase Upregulation and Intra-tumoral Melanin Accumulation: A Case Report with a Literature Review.
    Nezu M; Hirotsu Y; Amemiya K; Tateno T; Takizawa S; Inoue M; Mochizuki H; Hosaka K; Chik C; Oyama T; Omata M
    Intern Med; 2023 Jul; 62(13):1895-1905. PubMed ID: 36384901
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Next-generation Sequencing as a Potential Diagnostic Adjunct in Distinguishing Between Desmoplastic Melanocytic Neoplasms.
    Roth A; Boutko A; Lampley N; Dhillon S; Hagstrom M; Olivares S; Dittman D; Jennings L; Santana Dos Santos L; Busam K; Gerami P
    Am J Surg Pathol; 2023 Mar; 47(3):318-325. PubMed ID: 36383901
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Mutational Profile and Potential Molecular Therapeutic Targets of Pheochromocytoma.
    Ma X; Ling C; Zhao M; Wang F; Cui Y; Wen J; Ji Z; Zhang C; Chen S; Tong A; Li Y
    Front Endocrinol (Lausanne); 2022; 13():921645. PubMed ID: 35966080
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 28.